Borgmann V, Hardt W, Schmidt-Gollwitzer M, Adenauer H, Nagel R
Lancet. 1982 May 15;1(8281):1097-9. doi: 10.1016/s0140-6736(82)92279-6.
Nine patients with advanced carcinoma of the prostate were treated with the luteinising-hormone-releasing-hormone agonist buserelin (2 mg/day subcutaneously for 3 days then 0.4-1.2 mg/day intranasally for up to 24 weeks). There was a rise in luteinising-hormone levels during the first few days of treatment, but levels fell after 3 weeks and remained lower than normal after 24 weeks' treatment. In patients receiving 0.6-1.2 mg buserelin per day testosterone levels fell to less than 1 ng/ml within 3 weeks and were still as low as those found in surgically castrated men after 24 weeks. Histology showed regressive changes in some tumours after 3-6 months' buserelin treatment similar to those seen in surgically castrated men. Buserelin treatment may be an alternative to surgery in patients with advanced carcinoma of the prostate.
9例晚期前列腺癌患者接受了促黄体激素释放激素激动剂布舍瑞林治疗（皮下注射2毫克/天，共3天，然后鼻内给药0.4 - 1.2毫克/天，持续24周）。治疗开始的头几天促黄体激素水平升高，但3周后水平下降，24周治疗后仍低于正常水平。每日接受0.6 - 1.2毫克布舍瑞林治疗的患者，睾酮水平在3周内降至低于1纳克/毫升，24周后仍与手术去势男性的水平一样低。组织学检查显示，布舍瑞林治疗3 - 6个月后，部分肿瘤出现退行性变化，类似于手术去势男性所见。对于晚期前列腺癌患者，布舍瑞林治疗可能是手术的替代方案。
